Top

Published in:

Open Access 01-12-2021 | Peritoneal Cancer | Research article

Validation of ¹⁸F-FDG PET/MRI and diffusion-weighted MRI for estimating the extent of peritoneal carcinomatosis in ovarian and endometrial cancer -a pilot study

Authors: Björg Jónsdóttir, Montserrat Alemany Ripoll, Antonina Bergman, Ilvars Silins, Inger Sundström Poromaa, Håkan Ahlström, Karin Stålberg

Published in: Cancer Imaging | Issue 1/2021

Abstract

Background

The extent of peritoneal carcinomatosis is difficult to estimate preoperatively, but a valid measure would be important in identifying operable patients.

The present study set out to validate the usefulness of integrated ¹⁸F-FDG PET/MRI, in comparison with diffusion-weighted MRI (DW-MRI), for estimation of the extent of peritoneal carcinomatosis in patients with gynaecological cancer.

Methods

Whole-body PET/MRI was performed on 34 patients with presumed carcinomatosis of gynaecological origin, all scheduled for surgery. Two radiologists evaluated the peritoneal cancer index (PCI) on PET/MRI and DW-MRI scans in consensus. The surgeon estimated PCI intraoperatively, which was used as the gold standard.

Results

Median total PCI for PET/MRI (21.5) was closer to surgical PCI (24.5) (p = 0.6), than DW-MRI (median PCI 20.0, p = 0.007). However, both methods were highly correlated with the surgical PCI (PET/MRI: β = 0.94 p < 0.01, DW-MRI: β = 0.86, p < 0.01). PET/MRI was more accurate (p = 0.3) than DW-MRI (p = 0.001) when evaluating patients at primary diagnosis but no difference was noted in patients treated with chemotherapy. PET/MRI was superior in evaluating high tumour burden in inoperable patients. In the small bowel regions, there was a tendency of higher sensitivity but lower specificity in PET/MRI compared to DW-MRI.

Conclusions

Our results suggest that FDG PET/MRI is superior to DW-MRI in estimating total spread of carcinomatosis in gynaecological cancer. Further, the greatest advantage of PET/MRI seems to be in patients at primary diagnosis and with high tumour burden, which suggest that it could be a useful tool when deciding about operability in gynaecological cancer.

Available only for authorised users

Sant M, Chirlaque Lopez MD, Agresti R, Sanchez Perez MJ, Holleczek B, Bielska-Lasota M, et al. Survival of women with cancers of breast and genital organs in Europe 1999-2007: results of the EUROCARE-5 study. Eur J Cancer. 2015;51(15):2191–205. https://doi.org/10.1016/j.ejca.2015.07.022.CrossRefPubMed

Klint A, Tryggvadottir L, Bray F, Gislum M, Hakulinen T, Storm HH, et al. Trends in the survival of patients diagnosed with cancer in female genital organs in the Nordic countries 1964-2003 followed up to the end of 2006. Acta Oncol. 2010;49(5):632–43. https://doi.org/10.3109/02841861003691945.CrossRefPubMed

Socialstyrelsen. Cancerincidens i sverige 2013 [Available from: http://www.socialstyrelsen.se/Lists/Artikelkatalog/Attachments/19613/2014-12-10.pdf. Accessed 4 Dec 2020.

Bristow RE, Tomacruz RS, Armstrong DK, Trimble EL, Montz FJ. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol. 2002;20(5):1248–59. https://doi.org/10.1200/JCO.2002.20.5.1248.CrossRefPubMed

Luyckx M, Leblanc E, Filleron T, Morice P, Darai E, Classe JM, et al. Maximal cytoreduction in patients with FIGO stage IIIC to stage IV ovarian, fallopian, and peritoneal cancer in day-to-day practice: a retrospective French multicentric study. Int J Gynecol Cancer. 2012;22(8):1337–43. https://doi.org/10.1097/IGC.0b013e31826a3559.CrossRefPubMed

Barlin JN, Puri I, Bristow RE. Cytoreductive surgery for advanced or recurrent endometrial cancer: a meta-analysis. Gynecol Oncol. 2010;118(1):14–8. https://doi.org/10.1016/j.ygyno.2010.04.005.CrossRefPubMed

Jacquet P, Sugarbaker PH. Clinical research methodologies in diagnosis and staging of patients with peritoneal carcinomatosis. In: Sugarbaker PH, editor. Peritoneal Carcinomatosis: principles of management. Boston: Springer US; 1996. p. 359–74. https://doi.org/10.1007/978-1-4613-1247-5_23.CrossRef

Tentes AAK, Tripsiannis G, Markakidis SK, Karanikiotis CN, Tzegas G, Georgiadis G, et al. Peritoneal cancer index: a prognostic indicator of survival in advanced ovarian cancer. Eur J Surg Oncol. 2003;29(1):69–73. https://doi.org/10.1053/ejso.2002.1380.CrossRefPubMed

Lampe B, Kroll N, Piso P, Forner DM, Mallmann P. Prognostic significance of Sugarbaker's peritoneal cancer index for the operability of ovarian carcinoma. Int J Gynecol Cancer. 2015;25(1):135–44. https://doi.org/10.1097/IGC.0000000000000327.CrossRefPubMed

10.

Schmidt S, Meuli R, Achtari C, Prior J. Peritoneal Carcinomatosis in primary ovarian Cancer staging comparison between MDCT, MRI, and 18F-FDG PET/CT. Clin Nucl Med. 2015;40(5):371–7. https://doi.org/10.1097/RLU.0000000000000768.CrossRefPubMed

11.

Suidan RS, Ramirez PT, Sarasohn DM, Teitcher JB, Mironov S, Iyer RB, et al. A multicenter prospective trial evaluating the ability of preoperative computed tomography scan and serum CA-125 to predict suboptimal cytoreduction at primary debulking surgery for advanced ovarian, fallopian tube, and peritoneal cancer. Gynecol Oncol. 2014;134(3):455–61. https://doi.org/10.1016/j.ygyno.2014.07.002.CrossRefPubMedPubMedCentral

12.

Mazzei MA, Khader L, Cirigliano A, Cioffi Squitieri N, Guerrini S, Forzoni B, et al. Accuracy of MDCT in the preoperative definition of peritoneal Cancer index (PCI) in patients with advanced ovarian cancer who underwent peritonectomy and hyperthermic intraperitoneal chemotherapy (HIPEC). Abdom Imaging. 2013;38(6):1422–30. https://doi.org/10.1007/s00261-013-0013-9.CrossRefPubMed

13.

Takekuma M, Maeda M, Ozawa T, Yasumi K, Torizuka T. Positron emission tomography with 18F-fluoro-2-deoxyglucose for the detection of recurrent ovarian cancer. Int J Clin Oncol. 2005;10(3):177–81. https://doi.org/10.1007/s10147-005-0489-6.CrossRefPubMed

14.

Xu B, Ma J, Jiang G, Wang Y, Ma Q. Diagnostic value of positron emission tomography (PET) and PET/computed tomography in recurrent/metastatic ovarian cancer: a meta-analysis. J Obstet Gynaecol Res. 2017;43(2):378–86. https://doi.org/10.1111/jog.13222.CrossRefPubMed

15.

Low RN, Barone RM, Lucero J. Comparison of MRI and CT for predicting the peritoneal Cancer index (PCI) preoperatively in patients being considered for cytoreductive surgical procedures. Ann Surg Oncol. 2015;22(5):1708–15. https://doi.org/10.1245/s10434-014-4041-7.CrossRefPubMed

16.

Michielsen K, Dresen R, Vanslembrouck R, De Keyzer F, Amant F, Mussen E, et al. Diagnostic value of whole body diffusion-weighted MRI compared to computed tomography for pre-operative assessment of patients suspected for ovarian cancer. Eur J Cancer. 2017;83:88–98. https://doi.org/10.1016/j.ejca.2017.06.010.CrossRefPubMed

17.

Rosenkrantz AB, Friedman K, Chandarana H, Melsaether A, Moy L, Ding YS, et al. Current status of hybrid PET/MRI in oncologic imaging. AJR Am J Roentgenol. 2016;206(1):162–72. https://doi.org/10.2214/AJR.15.14968.CrossRefPubMed

18.

Bailey DL, Antoch G, Bartenstein P, Barthel H, Beer AJ, Bisdas S, et al. Combined PET/MR: the real work has just started. Summary report of the third international workshop on PET/MR imaging; February 17-21, 2014, Tubingen, Germany. Mol Imaging Biol. 2015;17(3):297–312. https://doi.org/10.1007/s11307-014-0818-0.CrossRefPubMedPubMedCentral

19.

Beiderwellen K, Grueneisen J, Ruhlmann V, Buderath P, Aktas B, Heusch P, et al. [(18) F] FDG PET/MRI vs. PET/CT for whole-body staging in patients with recurrent malignancies of the female pelvis: initial results. Eur J Nucl Med Mol Imaging. 2015;42(1):56–65. https://doi.org/10.1007/s00259-014-2902-8.CrossRefPubMed

20.

Grueneisen J, Schaarschmidt BM, Beiderwellen K, Schulze-Hagen A, Heubner M, Kinner S, et al. Diagnostic value of diffusion-weighted imaging in simultaneous 18F-FDG PET/MR imaging for whole-body staging of women with pelvic malignancies. J Nucl Med. 2014;55(12):1930–5. https://doi.org/10.2967/jnumed.114.146886.CrossRefPubMed

21.

Grueneisen JBK, Heusch P, Gratz M, Schulze-Hagen A, Heubner M, et al. Simultaneous positron emission tomography/magnetic resonance imaging for whole-body staging in patients with recurrent gynecological malignancies of the pelvis. A comparison to whole-body magnetic resonance imaging alone. Investig Radiol. 2014;49(12):808–15. https://doi.org/10.1097/RLI.0000000000000086.CrossRef

22.

Schwenzer NF, Schmidt H, Gatidis S, Brendle C, Muller M, Konigsrainer I, et al. Measurement of apparent diffusion coefficient with simultaneous MR/positron emission tomography in patients with peritoneal carcinomatosis: comparison with 18F-FDG-PET. J Magn Reson Imaging. 2014;40(5):1121–8. https://doi.org/10.1002/jmri.24497.CrossRefPubMed

23.

Padhani AR, Koh DM, Collins DJ. Whole-body diffusion-weighted MR imaging in cancer: current status and research directions. Radiology. 2011;261(3):700–18. https://doi.org/10.1148/radiol.11110474.CrossRefPubMed

24.

Rosenbaum SJ, Lind T, Antoch G, Bockisch A. False-positive FDG PET uptake--the role of PET/CT. Eur Radiol. 2006;16(5):1054–65. https://doi.org/10.1007/s00330-005-0088-y.CrossRefPubMed

25.

Kostakoglu L, Agress H Jr, Goldsmith SJ. Clinical role of FDG PET in evaluation of cancer patients. Radiographics. 2003;23(2):315–40; quiz 533. https://doi.org/10.1148/rg.232025705.CrossRefPubMed

26.

Pandit-Taskar N, Schöder H, Gonen M, Larson SM, Yeung HW. Clinical significance of unexplained abnormal focal FDG uptake in the abdomen during whole-body PET. AJR Am J Roentgenol. 2004;183(4):1143–7. https://doi.org/10.2214/ajr.183.4.1831143.CrossRefPubMed

27.

Jónsdóttir B, Lomnytska M, Poromaa IS, Silins I, Stålberg K. The Peritoneal Cancer Index is a Strong Predictor of Incomplete Cytoreductive Surgery in Ovarian Cancer. Ann Surg Oncol. 2021;28(1):244–51. https://doi.org/10.1245/s10434-020-08649-6. Epub 2020 May 29.

Title: Validation of 18F-FDG PET/MRI and diffusion-weighted MRI for estimating the extent of peritoneal carcinomatosis in ovarian and endometrial cancer -a pilot study
Authors: Björg Jónsdóttir
Montserrat Alemany Ripoll
Antonina Bergman
Ilvars Silins
Inger Sundström Poromaa
Håkan Ahlström
Karin Stålberg
Publication date: 01-12-2021
Publisher: BioMed Central
Keywords: Peritoneal Cancer
Peritoneal Carcinomatosis
Ovarian Cancer
Ovarian Cancer
Endometrial Cancer
Endometrial Cancer
Published in: Cancer Imaging / Issue 1/2021
Electronic ISSN: 1470-7330
DOI: https://doi.org/10.1186/s40644-021-00399-2

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2021

Magnetic resonance imaging-based radiomics signature for preoperative prediction of Ki67 expression in bladder cancer

High resolution MRI-based radiomic nomogram in predicting perineural invasion in rectal cancer

Dual-energy CT quantitative parameters for evaluating Immunohistochemical biomarkers of invasive breast cancer

Implementing CT tumor volume and CT pleural thickness into future staging systems for malignant pleural mesothelioma

Role of barium enema examination for the diagnosis of submucosal invasion depth in T1 colorectal cancers

Application of contrast-enhanced CT radiomics in prediction of early recurrence of locally advanced oesophageal squamous cell carcinoma after trimodal therapy

Keynote webinar | Spotlight on antibody–drug conjugates in cancer